Halozyme Therapeutics Confirms It Anticipates $0 To Minimal Royalty Revenue Impact Based On Nov. 5 U.S. Centers For Medicare & Medicaid Services's Final Rule For Medicare Drug Price Negotiation Program

Benzinga
在Benzinga上打开